» Articles » PMID: 32648897

Repair Pathway Choice for Double-strand Breaks

Overview
Journal Essays Biochem
Specialty Biochemistry
Date 2020 Jul 11
PMID 32648897
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Deoxyribonucleic acid (DNA) is at a constant risk of damage from endogenous substances, environmental radiation, and chemical stressors. DNA double-strand breaks (DSBs) pose a significant threat to genomic integrity and cell survival. There are two major pathways for DSB repair: nonhomologous end-joining (NHEJ) and homologous recombination (HR). The extent of DNA end resection, which determines the length of the 3' single-stranded DNA (ssDNA) overhang, is the primary factor that determines whether repair is carried out via NHEJ or HR. NHEJ, which does not require a 3' ssDNA tail, occurs throughout the cell cycle. 53BP1 and the cofactors PTIP or RIF1-shieldin protect the broken DNA end, inhibit long-range end resection and thus promote NHEJ. In contrast, HR mainly occurs during the S/G2 phase and requires DNA end processing to create a 3' tail that can invade a homologous region, ensuring faithful gene repair. BRCA1 and the cofactors CtIP, EXO1, BLM/DNA2, and the MRE11-RAD50-NBS1 (MRN) complex promote DNA end resection and thus HR. DNA resection is influenced by the cell cycle, the chromatin environment, and the complexity of the DNA end break. Herein, we summarize the key factors involved in repair pathway selection for DSBs and discuss recent related publications.

Citing Articles

Impact of glycolysis enzymes and metabolites in regulating DNA damage repair in tumorigenesis and therapy.

Sun F, Li W, Du R, Liu M, Cheng Y, Ma J Cell Commun Signal. 2025; 23(1):44.

PMID: 39849559 PMC: 11760674. DOI: 10.1186/s12964-025-02047-9.


Tousled-like kinase loss confers PARP inhibitor resistance in BRCA1-mutated cancers by impeding non-homologous end joining repair.

Kim M, Kim B, Jeon J, Lee J, Jang H, Baek M Mol Med. 2025; 31(1):18.

PMID: 39844055 PMC: 11753094. DOI: 10.1186/s10020-025-01066-z.


Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells.

Zeng J, Nguyen M, Liu P, da Silva L, Levesque S, Lin L Cell Stem Cell. 2024; 32(2):191-208.e11.

PMID: 39672163 PMC: 11805672. DOI: 10.1016/j.stem.2024.11.001.


Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers.

Feghaly C, Challita R, Hadir H, Mobayed T, Bitar T, Harbi M Biomark Insights. 2024; 19:11772719241297168.

PMID: 39512649 PMC: 11542137. DOI: 10.1177/11772719241297168.


DNA damage-induced EMT controlled by the PARP-dependent chromatin remodeler ALC1 promotes DNA repair efficiency through RAD51 in tumor cells.

Rajabi F, Smith R, Liu-Bordes W, Schertzer M, Huet S, Londono-Vallejo A Mol Biol Cell. 2024; 35(12):ar151.

PMID: 39504452 PMC: 11656468. DOI: 10.1091/mbc.E24-08-0370.